Does diabetes prevention translate into reduced long-term vascular complications of diabetes?


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
08 2019
Historique:
received: 21 03 2019
accepted: 14 05 2019
pubmed: 5 7 2019
medline: 17 4 2020
entrez: 5 7 2019
Statut: ppublish

Résumé

The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed at ameliorating the major risk factors for type 2 diabetes, are of proven efficacy in reducing the development of type 2 diabetes in people with impaired glucose tolerance. While prevention of the hyperglycaemia characteristic of diabetes is arguably an important, clinically relevant outcome, a more compelling outcome with greater clinical significance is the prevention or reduction of the relatively diabetes-specific microvascular and less-specific cardiovascular disease (CVD) complications associated with diabetes. These complications cause the majority of morbidity and excess mortality associated with diabetes. Any reduction in diabetes should, logically, also reduce the occurrence of its long-term complications; however, most diabetes prevention trials have not been of sufficient duration to allow such an evaluation. The limited long-term data, largely from the Da Qing Diabetes Prevention Study (DQDPS) and the Diabetes Prevention Program (DPP) and their respective follow-up studies (DQDPOS and DPPOS), suggest a reduction in microvascular complications and amelioration of CVD risk factors. Only the DQDPOS and Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) studies have shown a reduction in CVD events and only DQDPOS has demonstrated a decrease in CVD and overall mortality. While these limited data are promising, whether diabetes prevention directly reduces complication-related morbidity and mortality remains unclear. Longer follow-up of prevention studies is needed to supplement the limited current clinical trial data, to help differentiate the effects of diabetes prevention itself from the means used to reduce diabetes development and to understand the balance among benefits, risks and costs of prevention.

Identifiants

pubmed: 31270584
doi: 10.1007/s00125-019-4928-8
pii: 10.1007/s00125-019-4928-8
pmc: PMC6818092
mid: NIHMS1533755
doi:

Substances chimiques

Hypoglycemic Agents 0
Rosiglitazone 05V02F2KDG
Metformin 9100L32L2N
Ramipril L35JN3I7SJ

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319-1328

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK048412
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048375
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048434
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048413
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK078907
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR016587
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048443
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048400
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002556
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048468
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048404
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048407
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048437
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048406
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048397
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048381
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048339
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048514
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048485
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048489
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048349
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048377
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Diabet Med. 2013 Jan;30(1):46-55
pubmed: 22812594
Acta Diabetol. 1991;28(2):169-73
pubmed: 1777654
Diabetes. 2008 Apr;57(4):995-1001
pubmed: 18223010
Lancet. 2006 Sep 23;368(9541):1096-105
pubmed: 16997664
N Engl J Med. 2012 Jul 26;367(4):319-28
pubmed: 22686416
Diabet Med. 1997 Jun;14(6):449-56
pubmed: 9212309
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):393-9
pubmed: 23175674
Diabetes Care. 2009 Apr;32(4):726-32
pubmed: 19171717
Diabetes. 2016 May;65(5):1370-9
pubmed: 26895792
Diabetes Care. 2016 Sep;39(9):1550-5
pubmed: 27411697
Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75
pubmed: 26377054
JAMA. 2003 Jul 23;290(4):486-94
pubmed: 12876091
N Engl J Med. 2006 Oct 12;355(15):1551-62
pubmed: 16980380
Diabetologia. 2011 Feb;54(2):300-7
pubmed: 21046360
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
PLoS One. 2009 May 21;4(5):e5656
pubmed: 19479072
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
pubmed: 24731674
Diabetes. 2013 Sep;62(9):3218-23
pubmed: 23761102
Diabetologia. 2014 Jul;57(7):1325-31
pubmed: 24771090
Diabetes Care. 2008 May;31(5):1007-14
pubmed: 18268075
N Engl J Med. 2010 Apr 22;362(16):1463-76
pubmed: 20228402
Lancet. 2002 Jun 15;359(9323):2072-7
pubmed: 12086760
Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886
pubmed: 28917545
Diabetologia. 2019 Jan;62(1):58-69
pubmed: 30334082
Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):382-93
pubmed: 18493227
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
Diabet Med. 2007 Feb;24(2):137-44
pubmed: 17257275
Diabetes Care. 2014 Aug;37(8):2253-60
pubmed: 24824548
Ann Intern Med. 2005 Apr 19;142(8):611-9
pubmed: 15838067
Diabetes Care. 2008 Apr;31(4):805-7
pubmed: 18184907
Lancet Diabetes Endocrinol. 2019 Jun;7(6):452-461
pubmed: 31036503
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
N Engl J Med. 2010 Apr 22;362(16):1477-90
pubmed: 20228403
Kidney Int. 2002 Sep;62(3):963-70
pubmed: 12164879
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Circulation. 2017 Jul 4;136(1):52-64
pubmed: 28476766
Lancet. 2008 May 24;371(9626):1783-9
pubmed: 18502303
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
J Am Coll Cardiol. 2009 Jun 2;53(22):2028-35
pubmed: 19477351
Diabet Med. 2017 Dec;34(12):1747-1755
pubmed: 28833481
Diabetes. 2018 Jul;67(7):1414-1427
pubmed: 29703844
N Engl J Med. 2011 Mar 24;364(12):1104-15
pubmed: 21428766

Auteurs

David M Nathan (DM)

Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA, USA. dppmail@bsc.gwu.edu.

Peter H Bennett (PH)

National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.

Jill P Crandall (JP)

Albert Einstein College of Medicine, Bronx, NY, USA.

Sharon L Edelstein (SL)

DPP/DPPOS Coordinating Center, Biostatistics Center, The George Washington University, 6110 Executive Blvd, Rockville, MD, USA.

Ronald B Goldberg (RB)

University of Miami School of Medicine, Miami, FL, USA.

Steven E Kahn (SE)

VA Puget Sound Health Center and University of Washington School of Medicine, Seattle, WA, USA.

William C Knowler (WC)

National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.

Kieren J Mather (KJ)

Indiana University School of Medicine, Indianapolis, IN, USA.

Sunder Mudaliar (S)

UC San Diego School of Medicine, San Diego, CA, USA.

Trevor J Orchard (TJ)

University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.

Marinella Temprosa (M)

DPP/DPPOS Coordinating Center, Biostatistics Center, The George Washington University, 6110 Executive Blvd, Rockville, MD, USA.

Neil H White (NH)

Washington University School of Medicine, St Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH